Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term phase 3 study of BIVV001 in previously treated severe hemophilia A
2020-002215-22Phase 3Active
- Sponsor
- Sanofi
- Start
- Dec 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efanesoctocog alfa in hemophilia A, sponsored by Sanofi. Primary endpoint: Number of participants with occurrence of inhibitor development. Started Dec 2020; status: active.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2020-002215-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002215-22.